Movement Tracking Devices for Cancer Patients on Chemotherapy

No longer recruiting at 2 trial locations

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Southern California

Disqualifiers: Hematologic malignancy, Symptomatic brain metastases, Movement disorder, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 60 days

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests movement tracking devices to help doctors understand the physical activity of cancer patients undergoing chemotherapy. Patients with solid tumors receiving strong chemotherapy treatments can participate. Participants will use devices like Microsoft Kinect, Microsoft Band, and accelerometers (devices that measure movement) to track their movements and report symptoms daily for 60 days. The trial suits those who can walk unaided, are comfortable using smartphones and wearable tech, and can read English, Spanish, or Traditional Mandarin. As an unphased trial, this study offers patients a unique opportunity to contribute to innovative research that may improve cancer care.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it does allow patients to be on corticosteroids for brain metastasis symptoms.

What prior data suggests that these movement tracking devices are safe for cancer patients?

Research has shown that wearable devices like the Microsoft Kinect 2 and Microsoft Band 2 are generally safe for patients, including those undergoing chemotherapy. Studies indicate that these devices are easy to use and can track physical activity without causing harm.

In one study, patients wore the Microsoft Band 2 for 60 days without experiencing major problems or discomfort. Another study found these devices helpful for patients, as they effectively monitor movement and activity.

Overall, these devices are considered safe and useful for tracking movement in cancer patients. The studies available have reported no serious side effects. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about using movement tracking devices for cancer patients on chemotherapy because these devices provide real-time insights into patients' physical activity levels and overall well-being. Unlike traditional assessments that rely on periodic check-ups, this approach continuously monitors patients with wearable technology, offering a more comprehensive view of how chemotherapy affects daily life. The combination of using a stationary Kinect device and a wearable wristband allows for precise tracking of movements and daily habits, which could lead to more personalized and effective care plans for patients.

What evidence suggests that these movement tracking devices are effective for monitoring physical activity in cancer patients?

Research has shown that wearable devices, like fitness trackers, effectively monitor physical activity in cancer patients. In this trial, participants will use movement tracking devices, such as the Microsoft Band 2 wristband, to track their activity. Studies indicate these devices help monitor movement and performance in those receiving chemotherapy. These devices have shown great promise in measuring and aiding recovery, providing valuable information about patient status during treatment. Patient-reported information and daily activity data from these devices offer insights into health and recovery progress. Overall, this technology serves as a helpful tool for improving care for cancer patients. ^{5 6 7 8 9}

Who Is on the Research Team?

Jorge Nieva

Principal Investigator

University of Southern California

Are You a Good Fit for This Trial?

This trial is for solid tumor patients undergoing chemotherapy who can consent, wear tracking devices, and report symptoms for up to 60 days. They must read English, Spanish or Mandarin, use a smartphone and wristband, be on specific chemo cycles without assistive walking devices. Excluded are those missing limbs, with symptomatic brain metastases or severe movement disorders.

Inclusion Criteria

Able to read English, Spanish, or Traditional Mandarin to complete patient reported outcomes

I am scheduled for at least 2 cycles of strong chemotherapy.

Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria

I am missing one or more limbs.

I have been diagnosed with a blood cancer.

I have brain metastases that are causing symptoms.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants perform physical activities and wear movement tracking devices while completing PRO questionnaires and weighing themselves daily

60 days

2 visits (in-person) on days 1 and 21

Follow-up

Participants are monitored for safety and effectiveness after treatment

90 days

What Are the Treatments Tested in This Trial?

Interventions

• Accelerometer

Trial Overview The study tests if movement tracking devices like Microsoft Kinect 2 and Band 2 can help optimize physical activity monitoring in solid tumor patients receiving day chemotherapy. It involves wearing sensors and using technology to provide daily health data.

How Is the Trial Designed?

Group I: Observational (physical activity, PROs) Experimental Treatment 4 Interventions

Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.

Who Is Running the Clinical Trial?

University of Southern California

Lead Sponsor

Trials

956

Recruited

1,609,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12395252/

The use of wearable technology in studies in older adults ... Most studies used wearable data to measure recovery (19 studies, 61%). Physical activity was the most studied wearable outcome (27 studies, 87%) ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7531613/

Use of Wearable Activity Tracker in Patients With Cancer ... PRO data included daily body weight measured on a provided home scale and daily questionnaires based on Patient-Reported Outcomes Measurement ...

3. nature.com nature.com/articles/s41598-024-53025-z

Harnessing physical activity monitoring and digital ... Wearable activity sensors also demonstrated good potential for tracking mobility performance in chemotherapy patients and showed significant ...

4. ascopubs.org ascopubs.org/doi/10.1200/OP.2024.20.10_suppl.427

Associations between wearable device metrics and ... This study assesses associations between performance status, home-based wearable device metrics, and patient-reported outcomes (PROs) among adults with cancer.

5. academic.oup.com academic.oup.com/oncolo/article/29/4/e419/7424533

Use of Wearable Devices in Oncology Patients: A Systematic ... Wearable devices may provide valuable data for the purposes of treatment monitoring, prognostication, and rehabilitation.

6. withpower.com withpower.com/trial/movement-tracking-devices-for-cancer-patients-on-chemotherapy-7923b

Movement Tracking Devices for Cancer Patients on ... This clinical trial studies movement tracking devices in optimizing and monitoring physical activity in patients with solid tumors undergoing chemotherapy ...

7. ascopubs.org ascopubs.org/doi/10.1200/CCI.20.00010

Quantified Kinematics to Evaluate Patient Chemotherapy ... Patients' overall physical activity was tracked via the Microsoft Band 2 wrist motion sensor for a 10-hour period daily over a 60-day study ...

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10048707/

Use of Wearable Activity-Monitoring Technologies to Promote ... Eighteen of these studies included post-treatment cancer survivors, eight were on active cancer treatment, and two were long-term cancer survivor studies.

9. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9068515/

Effect and feasibility of wearable physical activity trackers ... Findings from a small number of studies indicate that the devices are acceptable and that physical activity tracker and pedometer-based interventions are ...